Patents by Inventor Yasushi HIRAMINE
Yasushi HIRAMINE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11434472Abstract: The present invention provides a compound of formula (1) or a salt thereof wherein ring Q1 is optionally-substituted C6-10 aryl, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is C1-4 alkylene which may be optionally substituted with 1 to 3 fluorine atoms or C3-7 cycloalkyl; W2 is —NR4aC(O)—, etc. wherein R4a is hydrogen atom or C1-6 alkyl; ring Q2 is optionally-substituted C6-10 aryl, etc., which has an inhibitory effect on the sphere-forming ability of cancer cells and is useful an agent for removing iPS cells.Type: GrantFiled: December 19, 2017Date of Patent: September 6, 2022Assignee: Sumitomo Pharma Co., Ltd.Inventors: Yasushi Hiramine, Masayo Fujiwara, Hitoshi Ban, Futoshi Hasegawa
-
Publication number: 20220119764Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.Type: ApplicationFiled: January 3, 2022Publication date: April 21, 2022Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yasushi HIRAMINE, Yoshiki SASAI (deceased), Masayo TAKAHASHI
-
Publication number: 20220112457Abstract: The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.Type: ApplicationFiled: December 22, 2021Publication date: April 14, 2022Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yasushi HIRAMINE, Yoshiki SASAI (deceased), Masayo TAKAHASHI
-
Patent number: 11214771Abstract: The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.Type: GrantFiled: October 23, 2015Date of Patent: January 4, 2022Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi Kuwahara, Suguru Yamasaki, Yasushi Hiramine, Yoshiki Sasai, Masayo Takahashi
-
Patent number: 11214772Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.Type: GrantFiled: October 23, 2015Date of Patent: January 4, 2022Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi Kuwahara, Suguru Yamasaki, Yasushi Hiramine, Yoshiki Sasai, Masayo Takahashi
-
Publication number: 20190390172Abstract: The present invention provides a compound of formula (1) or a salt thereof wherein ring Q1 is optionally-substituted C6-10 aryl, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is C1-4 alkylene which may be optionally substituted with 1 to 3 fluorine atoms or C3-7 cycloalkyl; W2 is —NR4aC(O)—, etc. wherein R4a is hydrogen atom or C1-6 alkyl; ring Q2 is optionally-substituted C6-10 aryl, etc., which has an inhibitory effect on the sphere-forming ability of cancer cells and is useful an agent for removing iPS cells.Type: ApplicationFiled: December 19, 2017Publication date: December 26, 2019Inventors: Yasushi Hiramine, Masayo Fujiwara, Hitoshi Ban, Futoshi Hasegawa
-
Publication number: 20170313981Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.Type: ApplicationFiled: October 23, 2015Publication date: November 2, 2017Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yasushi HIRAMINE, Yoshiki SASAI, Masayo TAKAHASHI
-
Publication number: 20170313976Abstract: The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.Type: ApplicationFiled: October 23, 2015Publication date: November 2, 2017Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yasushi HIRAMINE, Yoshiki SASAI, Masayo TAKAHASHI